UP!

ALIM $5.62   View long term graphs

Alimera Sciences
Type
Public (NASDAQ: ALIM)
Industry Pharmaceutical company, health care, biotechnology
Founded 2003
Headquarters Alpharetta, Georgia, USA
Key people
Dan Myers, CEO
Rick Eiswirth, COO, CFO
Susan Caballa, SVP Regulatory
Ken Green, CSO
Dave Holland, SVP, Sales and Marketing
Philip Ashman, SVP, Managing Director Europe
Products Pharmaceuticals
Website www.alimerasciences.com

Alimera Sciences, Inc. is a biopharmaceutical company based in Alpharetta, Georgia that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Their main focus is on diseases affecting the back of the eye, or retina.

Alimera was founded in June 2003 by Dan Myers, Daniel White, Dave Holland and Mark Testerman. Three of the founders were previously part of Ciba Vision Ophthalmics, which was renamed Novartis Ophthalmics following a merger.

In 2004, Alimera Sciences introduced Soothe Emollient (Lubricant) Eye Drops for people with dry eyes. Soothe was the first lubricant eye drop to feature Restoryl, a lipid restorative that works to re-establish the lipid (oily) layer of tears, promoting sustained moisture retention. Soothe was a mineral oil in water emulsion developed by Chris Brancewicz (then at Clarkson University) for Ocular Research of Boston during 1996-2001. Soothe was sold to Bausch & Lomb in August 2007.

In 2006, Alimera Sciences developed and submitted for U.S. Food and Drug Administration (FDA) approval an application for a prescription to over-the-counter drug switch of 0.025% ketotifen fumarate, for the temporary relief of ocular itch. This product, Alaway, was approved by the FDA in December 2006 and was sold along with a potential future line extension to Bausch & Lomb, which began marketing Alaway in Spring 2007.

Alimera conducted two Phase 3 pivotal clinical trials (collectively known as the FAME Study) for ILUVIEN involving 956 patients in sites across the United States, Canada, Europe and India to assess the efficacy and safety of ILUVIEN at two dose levels. ILUVIEN is a sustained release intravitreal implant that delivers sub-microgram levels of fluocinolone acetonide (FAc) for 36 months. The company submitted the ILUVIEN New Drug Application (NDA) to the FDA in June 2010 and was granted priority review in August 2010. In December 2010, November 2011, and October 2013 the FDA issued Complete Response Letters (CRL) stating that it was unable to approve a NDA for ILUVIEN. Alimera met with the FDA in December 2013 and entered into labeling discussions. As a result, the company plans to refile with the FDA in early 2014.

In July 2010, a Marketing Authorization Application (MAA) for ILUVIEN was submitted to seven European countries via the Decentralized Regulatory Procedure (DCP) with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) serving as the Reference Member State (RMS). The six Concerned Member States (CMS) include Austria, France, Germany, Italy, Spain and Portugal.

In February 2012, based on a consensus arrived upon by the RMS and the CMS, the MHRA issued its Final Assessment Report that ILUVIEN is approvable. The company was tasked with seeking individual marketing authorizations in each of the seven countries. As of January 2014, ILUVIEN has been approved in Austria, France, Germany, Portugal, Spain, and the U.K. for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In April 2013, Alimera began selling ILUVIEN in Germany and the UK, and intends to begin selling in France in 2014. ILUVIEN is available through the U.K. National Health Service. Alimera has filed with the Medicines and Healthcare Products Regulatory Agency in the U.K. as the Reference Member State for 10 additional European Union (EU) country approvals through the Mutual Recognition Procedure.

News

Alimera Sciences, Inc. 0.72% (healthcare)

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2020 2020-10-27 Future report Set alerts
Q2 2020 2020-07-29 0.00 0.00
Q1 2020 2020-04-29 -0.24 -0.24
Q4 2019 2020-02-26 0.08 0.08
Q3 2019 2019-10-29 -0.60 -0.60
Q2 2019 2019-07-29 -1.05 -1.05
Q1 2019 2019-04-29 -0.60 -0.60
Q4 2018 2019-02-18 -0.30 -0.30
Q3 2018 2018-11-05 5.85 5.85
Q2 2018 2018-07-30 -0.90 -0.90

Ratings

2016-05-05 Downgrade Cowen and Company Outperform to Market Perform
2016-03-07 Reiterated Rating Cowen and Company Outperform
2016-03-04 Lower Price Target Cantor Fitzgerald Buy $6.00 to $5.00
2016-01-19 Boost Price Target Cantor Fitzgerald Buy $6.00
2015-12-17 Reiterated Rating Cantor Fitzgerald Buy $10.00
2015-11-26 Lower Price Target Credit Suisse $5.00 to $4.00
2015-11-26 Lower Price Target Credit Suisse Group AG $5.00 to $4.00
2015-09-30 Reiterated Rating Cantor Fitzgerald Buy $10.00
2015-08-11 Reiterated Rating Cantor Fitzgerald Buy $10.00
2015-05-08 Set Price Target Cantor Fitzgerald Buy $10.00
2015-03-31 Reiterated Rating Cantor Fitzgerald Buy $10.00
2015-01-07 Initiated Coverage Cantor Fitzgerald Buy $10.00
2014-11-17 Initiated Summer Street Research Buy $12
2014-11-17 Initiated Coverage Summer Street Buy to Buy $12.00
2014-09-29 Boost Price Target Northland Securities Outperform $7.00 to $10.00
2014-03-03 Boost Price Target Northland Securities $7.00
2013-10-28 Upgrade Cowen Market Perform to Outperform
2013-10-28 Upgrade Cowen and Company Market Perform to Outperform
2013-10-08 Initiated Northland Capital Outperform $5
2013-10-08 Initiated Coverage Northland Securities Outperform $5.00
2013-10-07 Initiated Coverage Northland Securities Outperform $5.00
2011-11-14 Downgrade Rodman & Renshaw Mkt Outperform to Mkt Perform
2010-12-27 Reiterated Oppenheimer Outperform $16 to $14
2010-10-11 Initiated Rodman & Renshaw Mkt Outperform $13
2010-06-02 Initiated Oppenheimer Outperform $16
2016-05-05 Downgrade Cowen and Company Outperform to Market Perform
2016-03-07 Reiterated Rating Cowen and Company Outperform
2016-03-04 Lower Price Target Cantor Fitzgerald Buy $6.00 to $5.00
2016-01-19 Boost Price Target Cantor Fitzgerald Buy $6.00
2015-12-17 Reiterated Rating Cantor Fitzgerald Buy $10.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
ARMISTICE CAPITAL, LLC 17.16%  (6936000) ALIM / VICL /
BAVP, L.P. 9.89%  (3998718) ALIM /
Domain Partners VI, L.P. 8.88%  (3590931) ALDX / ALIM / CADX / MRNS / OCRX / RGDO / ZGNX /
Polaris Venture Management Co IV LLC May be part of 13(d) group 7.65%  (3090769) ALIM / CERU / XLRN /
Lee Patrick 7.46%  (3013793) ALIM /
Flynn James E Possible Member of 10% Group 1.80%  (728718) AAVL / ALIM / ASPX / ATRS / AUXL / AXGN / CASM / CYCC / DRNA / EHTH / EMAG / FIXX / HITK / LOXO / NURO / PRTO / REPH / RIGL / STRM / TRGT / TWTI / VNDA / XNPT /
Green Kenneth SVP & Chief Scientific Officer 0.57%  (231734) ALIM /
Myers C. Daniel President and CEO 0.49%  (199161) ALIM /
EISWIRTH RICHARD S JR COO & CFO 0.42%  (171770) ALIM / JSDA /
Holland David SVP of Sales & Marketing 0.41%  (165988) ALIM /
Caballa Susan SVP,Regulatory&Medical Affairs 0.20%  (79420) ALIM /
Roberts Calvin W. 0.19%  (75620) ALIM /
Ashman Philip SVP, EU Managing Director 0.14%  (56400) ALIM /
Sofinnova Management VIII, L.L.C. 0.10%  (40020) ALIM /
DP VI Associates, L.P. 0.09%  (34907) ALDX / ALIM / CADX / MRNS / OCRX / RGDO / ZGNX /
BRADLEY GLEN 0.02%  (10047) ALIM /
Pizzo Peter J. III 0.02%  (7500) ALIM /

Comments